| pubmed-article:9129014 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0040052 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0210630 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9129014 | lifeskim:mentions | umls-concept:C0150108 | lld:lifeskim |
| pubmed-article:9129014 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:9129014 | pubmed:dateCreated | 1997-6-3 | lld:pubmed |
| pubmed-article:9129014 | pubmed:abstractText | Thrombocytopenia caused by chemotherapy is an important cause of morbidity and mortality in the treatment of malignant disease. Recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is a potent stimulator of megakaryocytopoiesis and prevents chemotherapy-induced thrombocytopenia in preclinical studies. We administered PEG-rHuMGDF with filgrastim after dose-intensive chemotherapy to 41 patients with advanced cancers to determine its safety and effects on hematologic recovery. Carboplatin 600 mg/m2 and cyclophosphamide 1,200 mg/m2 were administered to patients with advanced cancer. Patients were randomly assigned to receive blinded study drug, either PEG-rHuMGDF or placebo (3-to-1 ratio), commencing the day after chemotherapy. PEG-rHuMGDF was given at doses of 0.03, 0.1, 0.3, 1.0, 3.0, and 5.0 microg per kilogram body weight by daily subcutaneous injection for between 7 and 20 days. All patients received concurrent filgrastim 5 microg per kilogram body weight per day until neutrophil recovery. Fifteen patients had received PEG-rHuMGDF alone in a previous phase I study. Platelet function and peripheral blood progenitor cells (PBPC) were assessed. PEG-rHuMGDF enhanced platelet recovery in a dose-related manner when compared with placebo. The platelet nadir occurred earlier in patients given PEG-rHuMGDF (P = .002) but there was no difference in the depth of the nadir. Recovery to baseline platelet count was achieved significantly earlier following PEG-rHuMGDF administration compared with placebo (median, 17 days for PEG-rHuMGDF 0.3 to 5.0 microg/kg versus 22 days for placebo, P = .014). In addition, platelet recovery was faster in patients who had previously received PEG-rHuMGDF, suggesting that pretreatment might be beneficial. Platelet function did not change during or after administration of PEG-rHuMGDF. Levels of PBPC on day 15 after chemotherapy were significantly greater in patients administered PEG-rHuMGDF 0.3 to 5.0 microg/kg and filgrastim compared with those given placebo plus filgrastim. PEG-rHuMGDF was well tolerated at all doses. Two patients given PEG-rHuMGDF had a thrombotic episode. PEG-rHuMGDF accelerates platelet recovery after moderately dose-intensive carboplatin and cyclophosphamide, and is likely to be clinically useful in treatment of chemotherapy-induced thrombocytopenia. Because it enhances mobilization of PBPC by filgrastim, PEG-rHuMGDF might also allow more efficient collection of stem cells for autologous or allogeneic transplantation. | lld:pubmed |
| pubmed-article:9129014 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9129014 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9129014 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9129014 | pubmed:month | May | lld:pubmed |
| pubmed-article:9129014 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:GreenM DMD | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:HUSS CSC | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:CohenBB | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:ClarkeKK | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:BegleyC GCG | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:ZalcbergJJ | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:CebonJJ | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:O'ByrneJJ | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:GriggA PAP | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:BasserR LRL | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:RaskoJ EJE | lld:pubmed |
| pubmed-article:9129014 | pubmed:author | pubmed-author:MenchacaD MDM | lld:pubmed |
| pubmed-article:9129014 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9129014 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9129014 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:9129014 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9129014 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9129014 | pubmed:pagination | 3118-28 | lld:pubmed |
| pubmed-article:9129014 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:meshHeading | pubmed-meshheading:9129014-... | lld:pubmed |
| pubmed-article:9129014 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9129014 | pubmed:articleTitle | Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. | lld:pubmed |
| pubmed-article:9129014 | pubmed:affiliation | Centre for Developmental Cancer Therapeutics, Parkville, Victoria, Australia. | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9129014 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9129014 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9129014 | lld:pubmed |
